Drugs / REM0046127
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04672135 Comparator | Nov 2020 → Apr 2022 | Alzheimer disease | reMYND | Completed | No outcome recorded |
| Phase 2 | NCT05478031 Comparator | Jun 2022 → Jun 2024 | Alzheimer disease | reMYND | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REM0046127 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04672135 ↗ |
| Modality | Small molecule | “REM0046127 is a small molecule intended for the oral treatment of subjects suffering from Alzheimer's disease (AD).” NCT05478031 ↗ |
| Route | Oral | “Each subject receives either a single dose (SAD) or a multiple dose (MAD) of REM0046127 as oral solution” NCT04672135 ↗ |